Form 4: Neurocrine Biosciences Director Acquires Restricted Stock Units

Director William H Rastetter of Neurocrine Biosciences acquired 2,869 Restricted Stock Units (RSUs) on May 22, 2024, which will vest on May 22, 2025.

Summary

• On May 22, 2024, William H Rastetter, a director of Neurocrine Biosciences Inc., acquired 2,869 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Neurocrine Biosciences' common stock upon vesting.
• The RSUs will vest in full on May 22, 2025.
• Following the transaction, Rastetter directly owns 2,869 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider activity, which can be seen as a positive sign of alignment with shareholder interests, but doesn't provide strong positive or negative signals.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, but the vesting of RSUs in the future is mentioned.

Industry Context

This is a routine disclosure of stock-based compensation to a company director, which is a common practice in the biotechnology industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options and restricted stock units to their executives and directors as part of their compensation packages.
• The size and vesting schedule of these grants are generally aligned with industry benchmarks for companies of similar size and stage of development.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment, as it aligns the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's health and future prospects.

Key Dates